TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05005234
Drug: GFH925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an oral tablet formulation
Study: NCT06035016
Drug: pyrotinib combined with Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w
Study: NCT06035016
Drug: treatment of physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of physician's choice
Study: NCT05586789
Drug: Ranquilon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 1 mg tablets 3 times per day for 28 days
Study: NCT05586789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets 3 times per day for 28 days
Study: NCT05365425
Drug: Choline fenofibrate
Normalized name: Choline Fenofibrate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: choline fenofibrate 178.8mg (135mg as fenofibric acid)
Study: NCT05365425
Drug: Policosanol
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: policosanol 10mg
Study: NCT05354349
Drug: PRA023 SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug
Study: NCT05354349
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05354349
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05568212
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice single-agent chemotherapy regimen
Study: NCT04230746
Drug: Bactrim DS 800Mg-160Mg Tablet
Normalized name: Bactrim DS 800mg-160mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: To study effect on urinary microbiome
Study: NCT04230746
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: To study effect on urinary microbiome
Study: NCT03737617
Drug: Cuvitru 20 % Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT04717986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months
Study: NCT06584032
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/m\^2 via IV infusion, on Day 1 every three weeks.
Study: NCT05598411
Drug: Oral Glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone 24mg qd, 2-week duration
Study: NCT05598411
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo 24mg qd, 2-week duration
Study: NCT05103046
Drug: UCT-03-008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally available kinase inhibitor
Study: NCT06078501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo buccal administration 2-3 hours prior to procedure
Study: NCT06079112
Drug: 9MW2821
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0/1.25/1.5 mg/kg, intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
Study: NCT05295459
Drug: LYR-210
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYR-210 drug matrix (mometasone furoate)
Study: NCT05295459
Drug: Sham procedure control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham procedure control
Study: NCT06498076
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of prophylactic norepinephrinebolus after spinal anesthesia induction. If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.
Study: NCT06584474
Drug: Azithromycin neubilization
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: nebulized azithromycin (Xithrone, Amoun, Egypt) that will be initiated from day 7 of birth in a dose of 20 mg/kg/day in two divided doses for 3 weeks till the time of primary outcome assessment (at 28 days of age). Azithromycin solution for nebulization will be prepared from intravenous vials containing 500 mg lyophilized powder. First, each lyophilized powder vial will be prepared with 5 ml normal saline according to the manufacturer's instruction. The reconstituted solution will be diluted with 28.5 ml normal saline to make a final concentration of 17.5 mg/ml according to clinical pharmacy recommendation. For nebulization of azithromycin, 0.6 ml of final drug prepared solution will be taken for every~1 kg body weight of patient, then made up to 3 ml of normal saline and will be administered by Aerogen Jet Nebulizer every 12 hours using 8 liter/min of medical air or by face mask if not mechanically ventilated. According to the manufacturer's declaration, prepared azithro
Study: NCT05897203
Drug: TAZCOV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal Syrup
Study: NCT06592027
Drug: PRECEDEX INJ★ 2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: this group will receive single dose of dexmedetomidine 0.5 mcg /kg in 50 ml normal saline over 10 min IV infusion
Study: NCT06592027
Drug: PRECEDEX INJ★ 2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of dexmedetomidine 1 mcg /kg in 50 ml normal saline over 10 min IV infusion
Study: NCT06185543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matches active drug in size, color and taste
Study: NCT03986086
Drug: MPH966
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP2D tablet
Study: NCT03986086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPH966 placebo table
Study: NCT05259189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single subcutaneous injection
Study: NCT06249802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month intake of matching placebo
Study: NCT06097416
Drug: Neoadjuvant Chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~The CRT regimen consists of the standard algorithms: a total of 5400-5600 cGy of radiation (4500 cGy to the pelvis, with an integrated boost to the primary tumour and involved nodes of 500 cGy followed by an option boost to the primary tumour and involved nodes) delivered in 27-28 fractions, respectively, of 180-200 cGy each over a 5-6 week period.
Study: NCT06097416
Drug: Total Neoadjuvant Therapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2- diaminocyclohexane with an oxalate ligand as a leaving group. Platinum content is 48.1% to 50.1%.~All patients received the same chemotherapy (FOLFOX) and long-course chemoradiotherapy (50.4 Gy in 28 fractions) before surgery.
Study: NCT04790916
Drug: RO7049665
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7049665, subcutaneous injection, Q2W.
Study: NCT05858216
Drug: Chlor-Trimeton.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Package dose of Chlor-Trimeton will be administered
Study: NCT04900116
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, US guided PENG block will be performed with 20 ml %0.9 NaCl solution using a 22 gauge 10 mm block needle (Control Group).
Study: NCT00000658
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000658
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000658
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06088784
Drug: ATH-399A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered drug in capsule form.
Study: NCT06088784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered drug in capsule form.
Study: NCT04423861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive matching placebo BID for 7 days.
Study: NCT05097014
Drug: CHF5993
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized metered dose inhaler (pMDI) 2 inhalations bid
Study: NCT05097014
Drug: CHF1535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized metered dose inhaler (pMDI) 2 inhalations bid
Study: NCT05305404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo to be administered once at 11:00PM
Study: NCT04290871
Drug: Nitric Oxide Gas
Normalized name: Nitric oxide gas
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inspired NO/N2 will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment (within 48 hours after initiation of mechanical ventilation). Weaning from NO will start after 48-h consecutive NO inhalation. The physicians will follow their own institutional weaning protocols.
Study: NCT05119101
Drug: Dexamedotomidine added to Magnesium sulfate
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: we will give dexamedotomidine and mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
Study: NCT05957380
Drug: DA-2803-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants are administered one tablet per day for 48 weeks
Study: NCT05957380
Drug: Placebo of DA-2803
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants are administered one tablet per day for 48 weeks
Study: NCT05957380
Drug: Placebo of DA-2803-R
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants are administered one tablet per day for 48 weeks
Study: NCT04762602
Drug: HMPL-306
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally QD in a 28-day continuous dosing treatment cycle
Study: NCT04575948
Drug: Base formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base formula is a negative control
Study: NCT05866315
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administer remifentanil
Study: NCT06374914
Drug: Intravesical Solution
Normalized name: Rimso-50 Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkalinization of urine 1 day before the procedure Emptying the bladder with a catheter before the procedure mixing 1000 mg gemcitabine in 50 ml saline 90 minutes after administration 37.5 mg docetaxel mixed 120 minutes after administration in 50 ml saline maintanence if there is a 6 week induction response
Study: NCT04733781
Drug: Tumescent Lidocaine and Epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of a relatively large volume (125ml to 250ml) of a relatively dilute solution of lidocaine (1gm/L) and epinephrine (1mg/L or 2mg/L).
Study: NCT04575103
Drug: Antipsychotic
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment \>0.5 DDD
Study: NCT05991401
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \[Period 2\] DA-8010 5mg, Clarithromycin 500mg
Study: NCT05603975
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Normal saline was administered intravenously at 0.1ml per kilogram of body weight 1min before the dressing change.
Study: NCT05710237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered once during the trial in combination with either risperidone 1 mg or psilocybin 25 mg.
Study: NCT04663282
Drug: INS068 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
Study: NCT05115630
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT06392282
Drug: MV-140
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MV-140 use - sublingual spray approved for recurrent UTI prevention
Study: NCT06192264
Drug: ASC40
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASC 40 tablets orally once daily
Study: NCT05064137
Drug: Tricalcium phosphate fluoride varnish, 5% F-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricalcium phosphate fluoride varnish, 5% F- ( Clinpro White Varnish ) is a remineralizing agent applied on tooth surface after mixing it with a brush onto the dosage guide.
Study: NCT06722534
Drug: Celecoxib 400mg
Normalized name: CELECOXIB 400MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the interventional group receive 200 mg celecoxib twice daily for 6 months
Study: NCT06722534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the control group receive identically appearing placebo twice daily for 6 months
Study: NCT05248152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
Study: NCT06220929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and Mecobalamin tablets look and smell the same.
Study: NCT05908825
Drug: Vitamin C with AHA Exfoliative Serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catalyst is a novel skincare product comprised of low concentrations of multiple hydroxy acids and will be randomly assigned as Product A or Product B to be applied to one side of the face.
Study: NCT05908825
Drug: Placebo serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo serum will be randomly assigned as Product A or Product B to be applied to one side of the face.
Study: NCT05117658
Drug: HA121-28 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA121-28 tablet, 450 mg, po, QD×21 days, every 4 weeks (28 days)
Study: NCT04704908
Drug: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
Study: NCT05264922
Drug: Tisseel Injectable Product
Normalized name: Tisseel Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue will provide an inert, biocompatible, viscous substance able to remain within the Rotator Cuff (RC) defect rather than injecting SVF cells in saline.
Study: NCT05969834
Drug: uHCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon)
Study: NCT05969834
Drug: rHCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle)
Study: NCT05605002
Drug: SSRIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
Study: NCT06410092
Drug: FTL001
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion every 2 weeks
Study: NCT06242652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous (SC) injection.
Study: NCT05766813
Drug: Lenrispodun
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenrispodun 30 mg tablets administered orally, once daily.
Study: NCT05766813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching tablets administered orally, once daily.
Study: NCT06277427
Drug: PRG-1801 （CAR-T against BCMA）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with refractory LN and ANCA-associated vasculitis will be treated with PRG-1801
Study: NCT06151457
Drug: Alpha-Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06151457
Drug: α-adrenergic receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT04871646
Drug: CKD-314 Placebo+SOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-314 placebo is administered intravenously and standard of care is also performed..
Study: NCT04960202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablet or capsule)
Study: NCT06516679
Drug: Consolidation #4(without daunorubicin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. Low Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, intrathecal methotrexate~3. Low Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. Low Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. Low Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Maintenance chemotherapy(about 2yrs) : Vincristine, Dexamethasone, 6-mercaptopurine, intrathecal methotrexate
Study: NCT06516679
Drug: Consolidation #4(with daunorubicin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. High Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, Daunorubicin intrathecal methotrexate~3. High Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. High Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. High Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Maintenance chemotherapy(about 2yrs) : Vincristine, Dexamethasone, 6-mercaptopurine, intrathecal methotrexate
Study: NCT06516679
Drug: Allogeneic hematopoietic stem cell transplantation after Consolidation #4(with daunorubicin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. High Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, Daunorubicin intrathecal methotrexate~3. High Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. High Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. High Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Allogeneic hematopoietic stem cell transplantation
Study: NCT06012552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: application as in the control group
Study: NCT05018533
Drug: TAKC-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Solution
Study: NCT05018533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Solution
Study: NCT06035757
Drug: Bridion 200 MG in 2 ML Injection
Normalized name: Bridion 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF or PTC.
Study: NCT05654818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is identical in appearance to the active treatment: a drinkable solution in ampoules that is clear, yellowish in color with a slightly lemony odor and an oily, slightly sweet, lemony taste.
Study: NCT05851261
Drug: PA3670
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as control
Study: NCT05528315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06120374
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients eligible for enrollment, postoperative adjuvant chemotherapy was initiated at about 4-6 weeks after surgery, for a total of 4 cycles, with the chemotherapy regimen of gemcitabine + cisplatin. Administration: Gemcitabine 1,000 mg/m2 on days 1 and 8 (completed within 30-60 minutes), cisplatin 70 mg/m2 on day 1.
Study: NCT06120374
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients eligible for enrollment, sequential adjuvant immuotherapy was initiated at about 4-6 weeks after surgery, Immunotherapeutic agents include (PD-1/PD-L1) to be used every 21 days postoperatively for one year.
Study: NCT06305832
Drug: Androgen deprivation therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator,and the dose and frequency of administration will be consistent with the prescription information
Study: NCT06522100
Drug: Intravenous administration of Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take intravenous administration of Methylprednisolone (500mg/100ml by IV over 30 minutes per day) for 3 days.